Drug
Natalizumab clinical trials
Also written Tysabri, BG00002 and Antegren.
- studies test it
- 58
- open now
- 2
- in phase 3
- 13
- first study started
- 2001
Keep track of what changes. Save the Natalizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
58 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 5 |
| 2003 | 2 |
| 2004 | 3 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 21
- Phase 3
- 13
- Phase 4
- 18
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 39 · Other 19
Biogen (39) · The Cleveland Clinic (1) · Washington University School of Medicine (1) · State University of New York at Buffalo (1) · King's College London (1) · John Levine (1) · Dana-Farber Cancer Institute (1) · Amsterdam UMC, location VUmc (1)
Often tested with
Tested in the same studies.
Glatiramer (2) · Interferon beta-1a (2) · Methylprednisolone (2) · Motixafortide (1) · Fingolimod (1)
Studies
Open first, then newest update. How each study uses Natalizumab is read from its arms, and is right about nine times in ten.
Testing it · 58
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Natalizumab
- Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)RecruitingPhase 2Queen Mary University of LondonNCT05418010Written as Tyruko Injectable Product
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingPhase 4The Cleveland ClinicNCT03535298Written as Early Highly Effective Therapies Group
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple SclerosisTerminatedPhase 3BiogenNCT05265728Written as Natalizumab
- Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)CompletedPhase 1Washington University School of MedicineNCT05618301Written as Natalizumab
- Natalizumab in Preventing Post-partum Relapses in Multiple SclerosisCompletedPhase 4State University of New York at BuffaloNCT03046251Written as Natalizumab
- Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic OsteosarcomaWithdrawnPhase 1/2Case Comprehensive Cancer CenterNCT03811886Written as Natalizumab
- A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedPhase 4BiogenNCT05532163Written as Natalizumab
- A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationCompletedPhase 3BiogenNCT03689972Written as Natalizumab
- Natalizumab Subcutaneous Immunogenicity and Safety StudyTerminatedPhase 2BiogenNCT02142192Written as natalizumab
- A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnPhase 4BiogenNCT00771043Written as TYSABRI and AVONEX
- Natalizumab and Chronic InflammationTerminatedPhase 4Vanderbilt University Medical CenterNCT05177718Written as Natalizumab 300 MG in 15 ML Injection
- Inflammatory Response In SchizophreniaCompletedPhase 1King's College LondonNCT03093064Written as Natalizumab
- Methylprednisolone During the Switch Between Natalizumab and FingolimodStatus unknownPhase 4University Hospital, Clermont-FerrandNCT02769689Written as natalizumab (NTZ)
- Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host DiseaseCompletedPhase 2John LevineNCT02133924Written as natalizumab
- Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal EpilepsyCompletedPhase 2BiogenNCT03283371Written as Natalizumab
- Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHDCompletedPhase 2Dana-Farber Cancer InstituteNCT02176031Written as Natalizumab
- Towards Personalized Dosing of Natalizumab in Multiple SclerosisCompletedPhase 4Amsterdam UMC, location VUmcNCT03516526Written as Natalizumab
- Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic StrokeCompletedPhase 2BiogenNCT02730455Written as natalizumab
- Tysabri Effects on Cognition and Neurodegeneration in Multiple SclerosisCompletedNot applicableUniversity of ChicagoNCT01071512Written as Tysabri
See all 58 studies that test Natalizumab →
As the comparator · 1 — what is tested is compared with Natalizumab
Codes
What other systems call Natalizumab · ClinicalTrials.gg INT006576
- MeSH (NLM) D000069442NatalizumabConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 3JB47N2Q2PNATALIZUMABConfirmed FDA, Wikidata
- RxNorm 354770Confirmed FDA, Wikidata
- Wikidata Q386119natalizumabConfirmed FDA, Wikidata
- NCI Thesaurus C77862NatalizumabOne source FDA
- DrugBank DB00108One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069442 | Natalizumab | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 3JB47N2Q2P | NATALIZUMAB | Confirmed FDA, Wikidata |
| RxNorm | 354770 | — | Confirmed FDA, Wikidata |
| Wikidata | Q386119 | natalizumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C77862 | Natalizumab | One source FDA |
| DrugBank | DB00108 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.